Aerie Pharmaceuticals, Inc (AERI) saw its loss widen to $25.79 million, or $0.76 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $22.70 million, or $0.85 a share. On the other hand, adjusted net loss for the quarter widened to $20.94 million, or $0.62 a share from a loss of $19.17 million or $0.72 a share, a year ago. The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $25.43 million, compared with an operating loss of $22.11 million in the previous year period.
“With the Phase 3 clinical trials for RhopressaTM behind us, we are now looking forward to upcoming data that we expect to report this quarter from our RoclatanTM Mercury 2 trial. Mercury 2 is a 90-day Phase 3 registration trial structured identically to the successful Mercury 1 trial, but without the 12-month safety component. The 12-month safety data from Mercury 1 is anticipated this summer. Looking beyond the U.S., we also plan to commence our first European clinical trial for RoclatanTM, Mercury 3, in the middle of this year, and initiate our RhopressaTM Phase 1 and Phase 2 activity later this year in preparation for our Phase 3 registration trials in Japan for that market,” said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
